newsfilter
← Latest News
GlobeNewswire·

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic